394 related articles for article (PubMed ID: 23517078)
1. VIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repair.
Waschek JA
Br J Pharmacol; 2013 Jun; 169(3):512-23. PubMed ID: 23517078
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.
Harmar AJ; Fahrenkrug J; Gozes I; Laburthe M; May V; Pisegna JR; Vaudry D; Vaudry H; Waschek JA; Said SI
Br J Pharmacol; 2012 May; 166(1):4-17. PubMed ID: 22289055
[TBL] [Abstract][Full Text] [Related]
3. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.
Delgado M; Jonakait GM; Ganea D
Glia; 2002 Aug; 39(2):148-61. PubMed ID: 12112366
[TBL] [Abstract][Full Text] [Related]
4. Pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors: distribution and involvement in the secretion of Podarcis sicula adrenal gland.
Valiante S; Prisco M; Sciarrillo R; De Falco M; Capaldo A; Gay F; Andreuccetti P; Laforgia V; Varano L
J Endocrinol; 2008 Feb; 196(2):291-303. PubMed ID: 18252952
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of interferon (IFN) gamma-induced Jak-STAT1 activation in microglia by vasoactive intestinal peptide: inhibitory effect on CD40, IFN-induced protein-10, and inducible nitric-oxide synthase expression.
Delgado M
J Biol Chem; 2003 Jul; 278(30):27620-9. PubMed ID: 12754213
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective potential of three neuropeptides PACAP, VIP and PHI.
Dejda A; Sokołowska P; Nowak JZ
Pharmacol Rep; 2005; 57(3):307-20. PubMed ID: 15985713
[TBL] [Abstract][Full Text] [Related]
7. Distribution of vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, nitric oxide synthase, and their receptors in human and rat sphenopalatine ganglion.
Csati A; Tajti J; Kuris A; Tuka B; Edvinsson L; Warfvinge K
Neuroscience; 2012 Jan; 202():158-68. PubMed ID: 22108610
[TBL] [Abstract][Full Text] [Related]
8. [Neuroprotective role of PACAP, VIP, and PHI in the central nervous system].
Sokołowska P; Dejda A; Nowak JZ
Postepy Hig Med Dosw (Online); 2004; 58():416-27. PubMed ID: 15577749
[TBL] [Abstract][Full Text] [Related]
9. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
10. Potential Crosstalk between the PACAP/VIP Neuropeptide System and Endoplasmic Reticulum Stress-Relevance to Multiple Sclerosis Pathophysiology.
Withana M; Castorina A
Cells; 2023 Nov; 12(22):. PubMed ID: 37998368
[TBL] [Abstract][Full Text] [Related]
11. The involvement of PACAP/VIP system in the synaptic transmission in the hippocampus.
Yang K; Lei G; Jackson MF; Macdonald JF
J Mol Neurosci; 2010 Nov; 42(3):319-26. PubMed ID: 20414742
[TBL] [Abstract][Full Text] [Related]
12. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP.
Leceta J; Gomariz RP; Martinez C; Abad C; Ganea D; Delgado M
Ann N Y Acad Sci; 2000; 921():92-102. PubMed ID: 11193883
[TBL] [Abstract][Full Text] [Related]
13. Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.
Tan YV; Waschek JA
ASN Neuro; 2011 Oct; 3(4):. PubMed ID: 21895607
[TBL] [Abstract][Full Text] [Related]
14. Neuropeptides shaping the central nervous system development: Spatiotemporal actions of VIP and PACAP through complementary signaling pathways.
Maduna T; Lelievre V
J Neurosci Res; 2016 Dec; 94(12):1472-1487. PubMed ID: 27717098
[TBL] [Abstract][Full Text] [Related]
15. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia.
Delgado M; Leceta J; Ganea D
J Leukoc Biol; 2003 Jan; 73(1):155-64. PubMed ID: 12525573
[TBL] [Abstract][Full Text] [Related]
17. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
18. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity.
Ganea D; Rodriguez R; Delgado M
Cell Mol Biol (Noisy-le-grand); 2003 Mar; 49(2):127-42. PubMed ID: 12887096
[TBL] [Abstract][Full Text] [Related]
19. Anorexigenic effects of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide in the chick brain are mediated by corticotrophin-releasing factor.
Tachibana T; Saito ES; Takahashi H; Saito S; Tomonaga S; Boswell T; Furuse M
Regul Pept; 2004 Aug; 120(1-3):99-105. PubMed ID: 15177926
[TBL] [Abstract][Full Text] [Related]
20. Pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) regulate murine neural progenitor cell survival, proliferation, and differentiation.
Scharf E; May V; Braas KM; Shutz KC; Mao-Draayer Y
J Mol Neurosci; 2008 Nov; 36(1-3):79-88. PubMed ID: 18629655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]